在心力衰竭中克服利尿剂抵抗的比较策略:一个网络元分析
Ivna Gcv Lima1, Jairo T Nunes2, Adriana C Luk2
1Instituto de Ensino e Pesquisa Hospital Sirio-Libanês, São Paulo, São Paulo, Brazil.
JACC. Advances
|February 24, 2026
概括
心力衰竭 (HF) 中的利尿剂耐药性可以通过各种药理学策略来管理. -葡萄糖共传输体2抑制剂显示有望减少住院治疗,而其他补充剂可以改善短期的液体排出,但需要仔细监测.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 利尿剂耐药性是心力衰竭 (HF) 中管理流体过载的重大挑战.
- 目前针对利尿剂耐药性的补充策略缺乏比较有效性和安全性数据.
- 了解最佳治疗途径对于改善患者的治疗结果至关重要.
研究的目的:
- 进行一个网络元分析,比较HF中尿剂耐药性的药理学策略.
- 用随机对照试验 (RCT) 评估各种治疗方法的疗效和安全性.
- 为耐药HF的临床决策提供基于证据的指导.
主要方法:
- 系统地搜索PubMed和Embase数据库 (2000年1月至2024年6月) 的相关RCT.
- 包括成人HF患者的尿素耐药性.
- 随机效应网络元分析,汇集尿液输出,体重变化,住院治疗,死亡率和急性损伤 (AKI) 的数据.
主要成果:
- 托尔瓦普坦和低剂量循环利尿剂加上托尔瓦普坦显著增加了72小时的尿量.
- 甲和托尔瓦普坦证明了72小时体重的最大标准化减轻.
- -葡萄糖共运输体2抑制剂 (dapagliflozin,empagliflozin) 减少了HF住院的发生.
- 高剂量的循环利尿剂和甲与AKI的风险增加有关.
结论:
- -葡萄糖共运输体2抑制剂可能会减少HF再入院,具有有利的安全性.
- 脏部分的补充疗法可以改善短期的脱血,但需要对AKI和电解质失衡进行监测.
- 治疗选择应该考虑绝对效应和置信区间,认识到比较排名的探索性.
相关概念视频
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:30Heart Failure V: Medical Management
400
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
400
01:22Heart Failure Drugs: β-Blockers
1.0K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
01:29Heart Failure II: Pathophysiology
1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
01:26Heart Failure Drugs: Inotropic Agents
1.6K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.6K